

## Activating innate and adaptive immunity to fight cancer

### Pioneering immune cell engagers

#### Affimed N.V.

Our mission at Affimed (Nasdaq: AFMD) is to create novel therapeutic options for patients suffering from cancer and other life-threatening diseases. With our differentiated approach to arm and deploy the body's innate and adaptive immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

#### Affimed's ROCK™ Platform - Redirected Optimized Cell Killing


Affimed's unique ROCK™ platform enables the generation of first-in-class tetravalent, multi-specific immune cell engagers. This proprietary platform supports innate and adaptive drug development (NK and T cell engagers) and, based on its modularity, allows for antibody engineering of highly customizable immune cell engagers tailored to different indications and settings. A prerequisite for redirected optimized cell killing enabling the development of effective therapies is the ability to utilize different antibody formats and immune effector cell types. Affimed's ROCK™ platform addresses this need.

#### Affimed's ROCK™ Platform

- Suitable for the development of both NK and T cell engagers, thus employing both innate and adaptive immunity to fight cancer
- Generates antibody candidates tailored to different indications and settings
- Supports the potential for tetravalent and multi-specific formats
- Allows for the generation of engagers with variable pharmacokinetic (PK) profiles
- Enables the generation of immune cell engagers with favorable manufacturing properties

ROCK™'s modularity is built on a toolbox of proprietary formats and long-standing engineering know-how: A combination of competencies essential for the construction of novel, potent and custom immune cell engagers.

#### Partnerships with Industry, Academia and Advocacy Groups



## Redirected Optimized Cell Killing (ROCK™)


Redirecting innate and adaptive immune cells with multi-specific antibodies to achieve optimized killing of malignant cells is a powerful novel approach for therapy of cancer patients.

## Affimed's Long-Standing Expertise

Affimed has long-standing expertise in drug development of differentiated immune cell engagers and protein engineering, enabling the design of a novel class of tetravalent, multi-specific formats.

### ROCK™ Platform

A versatile platform of immune cell engagers based on a proprietary toolbox and modularity



## Affimed Highlights

- ✓ Lead product candidate: AFM13 most advanced NK cell engager in clinical development
  - Positive efficacy data as monotherapy in HL and in CD30-positive lymphoma
  - Encouraging efficacy in combination with Keytruda® (best response preliminary data: ORR of 89% and CR rate of 44%)
  - Suitable for combinations with checkpoint inhibitors, adoptive NK cell transfer or cytokines
- ✓ Differentiated T cell-based approach with two molecules in clinical development based on Affimed's platform
- ✓ Unencumbered pipeline of clinical and preclinical assets based on tetravalent bispecific antibody formats

## Management Team

Proven track record in biotech, pharma, product development and finance

### Adi Hoess, PhD, CEO

- CEO since 2011
- Led AFMD IPO in 2014
- Co-founded MorphoSys

### Florian Fischer, PhD, CFO

- CFO since 2005
- Led AFMD IPO in 2014
- Deutsche Bank and KPMG

### Wolfgang Fischer, PhD, COO

- Joined 2017 from Sandoz (Novartis)
- Global Head Program&Project Mgmt
- Regional Medical Director Hematology

### Leila Alland, MD, CMO

- Joined 2018 from Tarveda Therapeutics
- Oncology lead at AZ, BMS and Novartis

### Martin Treder, PhD, CSO

- Joined 2015 from CT Atlantic (Swiss I/O)
- Co-founder U3 Pharma (targeted cancer therapeutics)

### Denise Mueller, Head Comm. Strat/BD

- Joined 2016 from Pfizer
- US & global marketing, Pfizer and Wyeth

**Affimed**  
Technologiepark  
Im Neuenheimer Feld 582  
69120 Heidelberg, Germany

**Contact Us**  
[info@affimed.com](mailto:info@affimed.com)  
[www.affimed.com](http://www.affimed.com)

